Dermatitis, Atopic Clinical Trial
— Secu_in_ADOfficial title:
A Randomized, Placebo-controlled, Double-blind Study to Scrutinize the Efficacy of Secukinumab in Patients With Moderate to Severe Atopic Dermatitis
Verified date | May 2020 |
Source | GWT-TUD GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall aim of this study is to assess the effects of a new treatment called Secukinumab in adults suffering from moderate to severe atopic dermatitis. Furthermore, the study shall support the extension of the approval for Secukinumab from psoriasis to atopic dermatitis. The effectiveness of Secukinumab is determined on the reduction of the eczema score EASI 50 (Eczema Area and Severity Index, a tool to measure the severity of atopic dermatitis) at week 4.
Status | Completed |
Enrollment | 22 |
Est. completion date | May 4, 2020 |
Est. primary completion date | May 4, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Atopic dermatitis (intrinsic disease without IgE mediated sensitization defined by negative history and negative SX-1 CAP FEIA or extrinsic disease defined by positive history and / or positive SX-1 CAP FEIA), 2. SCORAD index score = 25, 3. EASI = 16, 4. Male and female patients at the age of 18 to 85 years, 5. Signed Informed Consent, 6. Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed, 7. Subject is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, and physical examination, 8. Patients with stable chronic asthma, treated with inhaled corticosteroids, will be allowed to participate. Exclusion Criteria: 1. Other inflammatory skin disease than atopic dermatitis, 2. Use of cyclosporine, azathioprine, mycophenolate [wash-out period of 4 weeks]; Phototherapy (PUVA, NB-UVB, UVA1; [wash-out period of 2 weeks]), Dupilumab (Dupixent®; [wash-out period of 12 weeks]) 3. Subjects expected to be exposed to an undue safety risk if participating in the trial including chronic infections, 4. Contraindications of Secukinumab by label (i.e. approval for the treatment of psoriasis in the EU - refer to point 14 - 16 at the bottom of this section), 5. Current severe progressive or uncontrolled disease which in the judgment of the investigator renders the subject unsuitable for the trial, 6. Plans for administration of live vaccines during the study period, 7. Chronic infection, 8. Patients with instable chronic asthma, 9. Any chronic inflammatory bowel disease (e.g. Crohn's disease), 10. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>10 mIU/mL), 11. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 20 weeks after stopping treatment. Effective contraception is defined as either: 1. Barrier method: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicide (where available). Spermicides alone are not a barrier method of contraception and should not be used alone, The following methods are considered more effective than the barrier method and are also acceptable: 2. Total abstinence: When this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception), 3. Female sterilization: have had a surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment, 4. Male partner sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject, 5. Use of established oral, injected or implanted hormonal methods of contraception, intrauterine device (IUD) or intrauterine system (IUS) NOTE: Women are considered post-menopausal and not of child bearing potential if they have had: i. 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or • six months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL Or ii. Surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential. 12. History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening, 13. Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit (a report = 6 months is also accepted), 14. History of alcohol or drug abuse within 1 year of the screening visit, 15. Planned major surgical procedure during the patient's participation in this study, 16. Hypersensitivity against Secukinumab, 17. Active or reactive tuberculosis, 18. Participation in other clinical studies. |
Country | Name | City | State |
---|---|---|---|
Germany | Carl Gustav Carus University Hospital, Department of Dermatology | Dresden | |
Germany | Klinische Forschung Dresden GmbH | Dresden | |
Germany | SRH Wald-Klinikum Gera, Center for Clinical Studies | Gera | |
Germany | Hannover Medical School, Department for Dermatology, Allergy and Venereology | Hannover | |
Germany | SIBAmed Studienzentrum GmbH & Co KG | Leipzig |
Lead Sponsor | Collaborator |
---|---|
GWT-TUD GmbH | Novartis Pharmaceuticals |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction in EASI | Proportion of patients with a reduction of the eczema score EASI of at least 50%. The proportions are then compared between study arms. | week 4 (visit 4) | |
Secondary | Reduction of EASI | To compare the proportions of patients with a reduction of the eczema score EASI 50. | baseline (day 1, visit 0) and End of Trial (Arm A week 12 / Arm B week 16) | |
Secondary | Reduction of EASI | To compare the number of patients with a reduction of the eczema score EASI 50. | Arm A week 12 / Arm B week 16 | |
Secondary | Reduction in SCORAD (Scoring atopic dermatitis) | The number of patients with a reduction of 50 % in SCORAD index. | day 1, week 4 and Arm A week 12 / Arm B week 16 | |
Secondary | Change in pruritus score (Visual Analogue Scale) | To compare the proportion of patients with change in pruritus score (VAS) by 50 %. | day 1, week 4 and Arm A week 12 / Arm B week 16 | |
Secondary | Change in IGA Score (5-point Investigator's Global Assessment) | To compare the proportion of patients who achieve a score of "clear-0" or "almost clear-1" in the static IGA score compared to baseline. | Arm A week 12 / Arm B week 16 | |
Secondary | Serum biomarkers CCL17 and CCL22 | To compare the serum biomarkers CCL17 and CCL22. | day 1, week 4 and Arm A week 12 / Arm B week 16 | |
Secondary | Increase in DLQI (Dermatology Life Quality Index) | To compare the proportion of patients achieving increase in DLQI by 30 %. | day 1, week 4 and Arm A week 12 / Arm B week 16 | |
Secondary | Consumption of topical methylprednisolone aceponate | To evaluate the quantification of the consumption of topical methylprednisolone aceponate 0.1% in gram. | day 1, week 4 and Arm A week 12 / Arm B week 16 | |
Secondary | Serious and non-serious adverse drug reactions | To observe any serious adverse drug reactions and non-serious adverse drug reactions. | treatment phase (day 1 up to week 16), follow-up phase (week 20, week 24) | |
Secondary | Gender distribution in patients with atopic dermatitis | Subgroup analyses will be performed to compare the effects of treatment with Secukinumab in male and female patients. Therefore, the recorded gender data will be used and separately analyzed for the above mentioned primary and secondary endpoints. | study arm A week 4 and both study arms week 16 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Terminated |
NCT04086121 -
A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032
|
Phase 2 | |
Recruiting |
NCT04011215 -
Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)
|
N/A | |
Completed |
NCT04635072 -
Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis
|
Early Phase 1 | |
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT01945086 -
A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT00541255 -
A Long-Term Examination of Asthma From Childhood Through Adolescence
|
||
Terminated |
NCT04990440 -
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT02900131 -
Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients
|
Phase 2 | |
Recruiting |
NCT01631617 -
Effects of Treatments on Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT03672383 -
Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)
|
N/A | |
Completed |
NCT03634345 -
Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
|
Phase 1 | |
Enrolling by invitation |
NCT04761978 -
Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis
|
||
Completed |
NCT03663673 -
Effect of Different Skin Creams on TEWL
|
Phase 1 | |
Recruiting |
NCT05177744 -
Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
|
||
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Completed |
NCT02637206 -
Skin Irritation Study of GSK2894512 Cream
|
Phase 1 | |
Completed |
NCT05544591 -
Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT05094700 -
A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
|
N/A | |
Terminated |
NCT02582788 -
Bathing Additives in Pediatric Atopic Dermatitis
|
N/A |